12 min read0
November 18, 20260

Breakthrough Pancreatic Cancer Treatments Bring New Hope

Breakthrough Pancreatic Cancer Treatments Bring New Hope

On this page

family chief medical officer

In 2026, nearly 70,000 people in the U.S. will be diagnosed with pancreatic cancer. What makes pancreatic cancer one of the more difficult to treat cancers is that there is no early detection screening test for the disease and in its early stages it often causes no symptoms. Without screening or early symptoms, pancreatic cancer is usually diagnosed after it has spread beyond the pancreas and starts to affect other organs and nearby lymph nodes, which is called locally advanced pancreatic cancer.

Late stage detection makes pancreatic cancer more difficult to treat successfully, leading to low 5-year survival rates (13.7% when all stages and types of pancreatic cancer are included). Of course, an individual’s prognosis depends on a range of factors, including:

  • Type of pancreatic cancer: Adenocarcinoma is the most common type of pancreatic cancer and has an average 5-year survival rate of approximately 13%. The less common type of pancreatic cancer, neuroendocrine tumors, have much higher 5-year survival rates of around 50% when local and advanced cancer survival rates are averaged, with some studies noting even higher survival rates.
  • Whether the cancer has spread: Cancer that is confined to the pancreas is more treatable than cancer that has spread to nearby and distant organs and lymph nodes.
  • Whether the tumor can be surgically removed: If the tumor can be fully resected surgically, survival rates improve.
  • How aggressive the tumor is: High levels of the tumor marker CA 19-9 in the blood often indicate more aggressive or advanced disease.

New targeted pancreatic cancer therapy is improving survival rates for advanced cancer

A newly FDA-approved pancreatic cancer drug is changing the outlook for people diagnosed with metastatic pancreatic adenocarcinoma that has previously been treated with standard therapy. In pre-approval clinical studies, the drug, Daraxonrasib (brand name Rasonque) nearly doubled survival rates and progression-free survival from 6.6 months for patients treated with chemotherapy to 13.2 months for patients treated with a once a day pill form of Daraxonrasib.

About 90% of pancreatic cancers are driven by mutations in a gene called KRAS. Previously, KRAS was considered to be untreatable with medication. Daraxonrasib, however, works against these mutations because it targets a broad range of KRAS mutations at once, rather than just one. Daraxonrasib essentially locks the growth signal sent by the mutation, causing cancer cells to slow or stop growing, a process called RAS inhibition. Because it works against multiple RAS mutations, Daraxonrasib is called a pan-RAS inhibitor.

A new small study has also showing promise for Daraxonrasib’s use as a lung cancer treatment. Tumors shrank in more than 30% of study participants with the most common form of lung cancer, non-small-cell lung cancer. All study participants had a RAS tumor-promoting mutation and had previously been treated with standard therapies. A larger randomized study is getting underway.

A wearable medical device to treat pancreatic cancer

Another recently FDA-approved treatment for unresectable, locally advanced pancreatic cancer takes a very different approach. The wearable device called Optune Pax®, is a portable, non-invasive device that delivers alternating electrical fields, known as tumor treating fields (TTFields), to the abdomen. These fields disrupt the rapid cell division of cancer cells, while minimizing damage to healthy tissue. The treatment is combined with a standard chemotherapy regimen.

The therapy is administered through electrically insulated adhesive patches placed on the skin and connected to an electric field generator. The device is worn with the generator carried in a specially designed bag, allowing patients to receive continuous treatment. Only mild to moderate skin irritation was reported as a side effect.

Advanced surgical approach expands number of patients whose tumor can be resected

Because of the involvement of major intra-abdominal arteries and veins, operating on patients with locally advanced pancreatic cancer was previously not possible. But with novel surgical approaches that include arterial and venous reconstruction with the goal of organ preservation and maximal revascularization, outcomes are similar to patients diagnosed with earlier stages of the disease. This makes it possible to successfully resect complex tumors, excise the involved veins, and replace them with vein grafts from the patient’s leg and neck.

Some cancers once considered unresectable are now operable with this approach, and selected patients have achieved long‑term, disease‑free survival with outcomes comparable of patients with early‑stage pancreatic cancer.

New treatments and diagnostic tests in the pipeline

In addition to the newly FDA-approved pancreatic cancer treatments and improved surgical techniques, there are several new approaches to treatment in development as well as a blood test that has the potential to detect pancreatic cancer at an earlier stage.

Researchers at Memorial Sloan Kettering Cancer Center are in the early stages of testing an individualized therapeutic vaccine that uses messenger RNA. The vaccine is custom made for each patient and designed to stimulate the patient’s immune system via T cells so it can combat pancreatic cancer. A very small phase 1 trial was recently completed and a global stage 2 trial is now underway.

Other early stage research is exploring the effect of blocking a receptor that plays a role in inflammatory signaling in pancreatic cancer. Inhibiting the receptor reduced the number of immune suppressive cells and increased the activity of T cells, making chemotherapy and immunotherapy more effective. Other researchers have found peptides expressed by pancreatic cancer cells that could be potential targets for T-cell therapies.

There is also an investigational liquid biopsy (blood test) in development that in early testing was able to detect stage 1 and 2 pancreatic cancer as well as high-grade dysplasia, a precancerous condition. In the original study of 1,800 people, the test correctly identified stage 1 and stage 2 pancreatic cancer with 87% accuracy and high-grade dysplasia 64.3% of the time. A clinical trial of the test is recruiting participants.

Connect with PinnacleCare

For more information about how PinnacleCare’s Health Advisors could assist you with pancreatic cancer support, connect with us today.

Top 5 FAQs About Pancreatic Cancer & Latest Treatments

Pancreatic cancer often causes no symptoms in its early stages, and there is currently no early detection screening test for the disease.

Daraxonrasib, sold under the brand name Rasonque, is a newly FDA-approved targeted therapy for previously treated metastatic pancreatic adenocarcinoma.

Daraxonrasib is a pan-RAS inhibitor that targets a broad range of KRAS-related mutations and helps slow or stop cancer cell growth signals.

Optune Pax is a wearable, non-invasive device that delivers tumor-treating fields to the abdomen and is used with standard chemotherapy for unresectable, locally advanced pancreatic cancer.

An investigational liquid biopsy blood test is being studied for its potential to detect Stage 1 and 2 pancreatic cancer and high-grade dysplasia earlier.

PinnacleCare is a member of the Sun Life Financial Inc. (“Sun Life”) family of companies. PinnacleCare and its employees do not diagnose medical conditions, recommend treatment options or provide medical care, and any information or services provided should not be considered medical advice. Any medical decisions should be made only after consultation with and at the direction of your medical provider. Any person or entity who provides health care services following a referral or other service provided does so independently and not as an agent or representative of PinnacleCare.

© 2026 PinnacleCare International, LLC, Baltimore, MD. All rights reserved.

PCWC-10116-50 #4598123612 10/26 (exp. 10/28)

Published On: November 18, 2026Categories: Condition and Disease Management